Laurie Toich, Assistant Editor

Top news of the day from across the healthcare landscape.

More than 3000 patients with breast cancer have received radiation with the Xoft System.

Patients with obesity developed heart disease 4.3 years earlier.

Unhealthy eating habits involved with more than 400,000 deaths in 2014.

Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.

Eculizumab (Soliris) can reduce disease burden for patients with refractory generalized myasthenia gravis.

Soliris treats patients with refractory generalized myasthenia gravis.

Epalrestat could prevent metastasis in patients with basal-like triple-negative breast cancer.

High consumption of isoflavones reduced all-cause mortality in patients with breast cancer by 21%.

Repurposed drugs may provide new therapies for cancer.

Isoflavone supplements may influence outcomes among patients with breast cancer.

Top news of the day from across the healthcare landscape.

Niraparib (Zejula) FDA approved to treat epithelial ovarian, fallopian tube, or primary peritoneal cancers.

FDA approves Zejula for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Only 5% of patients knew their physician had received payments from a pharmaceutical or medical device company.

MSI-1436 reduced the size of scar tissue post-heart attack by 53% in mouse models.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

Children born to mothers with gestational diabetes have altered fat cells.

Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.

Equine-assisted therapy improved motor function in cerebral palsy and multiple sclerosis.

Top news of the day from across the healthcare landscape.

Corticosteroids, chemotherapy, and immunotherapy may all be used to treat castration-resistant prostate cancer.

Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.

Quiescent stem cells are dormant and are not impacted by cancer treatments.

Increasing expression of REV-ERB observed to decrease LDL cholesterol.

Real-world evidence suggests SGLT-2 can reduce all-cause mortality in diabetes patients.

Study suggests Medicare reform to help patients predict monthly medication costs.

Monthly and annual spending limits would likely benefit Part D enrollees.

Increased screen time observed to be associated with adiposity.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.